<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01364675</url>
  </required_header>
  <id_info>
    <org_study_id>12011</org_study_id>
    <nct_id>NCT01364675</nct_id>
  </id_info>
  <brief_title>Primary Prevention of Cardiovascular Disease (CVD) in Pre-diabetic &amp; Pre-hypertensive Subjects</brief_title>
  <acronym>PPCVD</acronym>
  <official_title>Primary Prevention of Cardiovascular Disease in Pre-diabetic &amp; Pre-hypertensive Subjects Using Multiple Risks Reduction Strategy: A Multi-center, Double-blind, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ramathibodi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ubon Ratchathani Public Health Office, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Health Security Office, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Government Pharmaceutical Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ramathibodi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treating pre-diabetic &amp; pre-hypertensive
      individuals using multiple drugs intervention (anti-hypertensive drugs (i.e., ACEI) plus
      anti-glycemic drug (i.e., metformin) plus anti-hyperlipidemic drug (statin)) would lower
      Cardiovascular Disease (CVD) events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The risks of CVD are not confined to a subset of established &quot;hypertensive&quot; or &quot;diabetic&quot;
      population, but also increase among those with suboptimal blood pressure and glycemic level,
      namely &quot;pre-hypertensive&quot; or &quot;pre-diabetic&quot; population. Evidence on the effectiveness of drug
      interventions to lower CVD events in pre-clinical stage population has been scant.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular Events</measure>
    <time_frame>4-year</time_frame>
    <description>Fatal or Non-fatal Myocardial Infarction, Angina Pectoris, Congestive Heart Failure, Coronary Revascularization, Fatal or Non-fatal Stroke, Amputation of Lower Extremities (non-traumatic cause)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Micro-vascular Complications</measure>
    <time_frame>4-year</time_frame>
    <description>Renal dysfunction, ESRD (on dialysis or kidney transplantation), Progression of Albuminuria, Retinopathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Diabetes</measure>
    <time_frame>4-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Hypertension</measure>
    <time_frame>4-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Individual Cardiovascular Disease</measure>
    <time_frame>4-year</time_frame>
    <description>Coronary Artery Disease - Myocardial Infarction, Angina Pectoris, Congestive Heart Failure, Coronary Revascularization
Stroke- Cerebral Hemorrhage, Cerebral Infarction, Subarachnoid Hemorrhage
Peripheral Artery Disease- Leg amputation, endovascular or surgical intervention in leg arteries</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8900</enrollment>
  <condition>Pre-diabetes</condition>
  <condition>Pre-hypertension</condition>
  <arm_group>
    <arm_group_label>Metformin+Enalapril+Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin+Enalapril+Simvastatin</intervention_name>
    <description>Poly-pill - composed of Metformin (500 mg), Enalapril (10 mg) and Simvastatin (10 mg) in single tablet given once daily after dinner for 4 years</description>
    <arm_group_label>Metformin+Enalapril+Simvastatin</arm_group_label>
    <other_name>Poly-pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>Identical Placebo Tablet</description>
    <arm_group_label>Placebo tablet</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-diabetes

          -  Pre-hypertensives

          -  LDL-Cholesterol &gt;= 100 &lt; 190 mg/dl

          -  BMI &gt;= 23

          -  Estimated GFR &gt;= 60 ml/min/1.73 m2 (MDRD equation)

          -  Willing to participate and provide written inform consent

        Exclusion Criteria:

          -  Current involved in other studied medications

          -  Regular use of corticosteroids

          -  Current use of weight loss medication

          -  History of renal disease

          -  Active liver disease including jaundice, chronic hepatitis with ALT &gt;= 2.5 the upper
             normal limit

          -  Active malignancy

          -  Major psychiatric disorder

          -  Diseases and medications that affect glucose tolerance (e.g. pheochromocytoma,
             Cushing's syndrome, acromegaly, steroid-dependent asthma, protease inhibitors,
             antipsychotics)

          -  Nursing women, pregnant women, or those that plan to become pregnant in the study
             period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phisitt Vejakama, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Section for clinical epidemiology and bioststistics, Faculty of medicine, Ramathibodi hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Phisitt Vejakama, M.D.</last_name>
    <phone>66849562882</phone>
    <email>toughcountrydoc@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ammarin Thakkinstian, Ph.D.</last_name>
    <phone>66818436266</phone>
    <email>raatk@mahidol.ac.th</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ubon ratchathani Public Health Office</name>
      <address>
        <city>Muang District</city>
        <state>Ubon ratchathani</state>
        <zip>34000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Phisitt Vejakama, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2011</study_first_submitted>
  <study_first_submitted_qc>June 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2011</study_first_posted>
  <last_update_submitted>June 1, 2011</last_update_submitted>
  <last_update_submitted_qc>June 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Phisitt Vejakama</name_title>
    <organization>Section for clinical epidemiology, Faculty of medicine, Ramathibodi hospital, Thailand</organization>
  </responsible_party>
  <keyword>Impaired fasting glucose</keyword>
  <keyword>Impaired glucose tolerance</keyword>
  <keyword>Pre-diabetes</keyword>
  <keyword>Pre-hypertensives</keyword>
  <keyword>Cardiovascular events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Prehypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

